Lung Squamous Cell Carcinoma Clinical Trial
Official title:
A Mechanism Study to Investigate the Difference in Efficacy of Neoadjuvant PD-1 Blockade Combined With Chemotherapy in the Treatment of IIA-IIIB Stage Lung Squamous Cell Carcinoma
To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy
The biobank of thoracic surgery department of Tangdu Hospital collected pre-treatment tissues from patients during endoscopy. The investigators retrospectively summarized the clinical characteristics of these patients and patients with operable locally advanced lung squamous cell carcinoma were selected and followed. The investigators plan to employ snRNA-seq and scRNA-seq respectively to profile 20 samples of paired pre-treatment and post-treatment tumors from ten patients (discovery cohort) to create a cell atlas for analysis, and spatial transcriptomics to examine 8 samples from four patients. In discovery cohort, estimated 5 patients achieve major pathological response (MPR) and 5 patients achieve non-MPR after NICB. After analyzing the results of discovery cohort, the investigators will collect frozen tissues and formalin-fixed, paraffin-embedded (FFPE) tissue from our biobank for bulk RNA-seq analysis or immunohistochemistry (IHC) staining as validation cohort to further investigate the predictive value and biological significance of our markers. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04267913 -
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)
|
Phase 2 | |
Not yet recruiting |
NCT03725423 -
Apatinib for Advanced Lung Squmamous Carcinoma
|
Phase 4 | |
Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
Recruiting |
NCT04132102 -
To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation
|
Phase 4 | |
Active, not recruiting |
NCT04152018 -
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
|
Phase 1 | |
Recruiting |
NCT05778253 -
The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
|
||
Recruiting |
NCT02876978 -
Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
|
Phase 1 | |
Completed |
NCT01807546 -
Oral Rigosertib for Squamous Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT01386385 -
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00334815 -
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
Recruiting |
NCT05782764 -
A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom
|
Phase 4 | |
Recruiting |
NCT05010330 -
Identify Prognostic Biomarkers of Lung Cancer
|
||
Recruiting |
NCT05024266 -
Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04802876 -
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
|
Phase 2 |